Krsnaa Diagnostics Limited's Board of Directors has approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for an extended five-year term. The decision, announced on February 22, 2026, reflects the company's confidence in his leadership and strategic vision for the healthcare diagnostics sector.

Board Decision and Regulatory Compliance

The Board of Directors, acting on recommendations from the Nomination and Remuneration Committee, has accorded approval for Mr. Mutha's re-appointment in accordance with the Companies Act, 2013, SEBI (LODR) Regulations, 2015, and other applicable regulatory provisions. The appointment is subject to shareholder approval through postal ballot.

Leadership Profile and Expertise

Mr. Rajendra Khivraj Mutha brings over two decades of specialized expertise in pharmacy and diagnostics to his executive role. As a certified Pharmacist accredited by the Maharashtra State Pharmacy Council, he leverages extensive industry knowledge to drive the company's strategic vision and operational excellence.

Key Leadership Areas

• Strategic Operations: Spearheads the company's operational excellence initiatives
• Community Health: Leads impactful outreach programs focused on community health, women, and children
• Corporate Social Responsibility: Champions CSR programmes that uplift underserved communities
• Healthcare Innovation: Recognized as a changemaker in Indian healthcare sector

Governance and Independence

The appointment maintains proper corporate governance standards, with Mr. Mutha confirmed as not being related to any other Directors on the company's Board. Additionally, he meets all regulatory compliance requirements and is not debarred from holding directorial positions by SEBI or any other regulatory authority.

Meeting Details and Regulatory Disclosure

The board meeting commenced at 18:30 Hrs. (IST) and concluded at 21:10 Hrs. (IST) on February 22, 2026. The company has filed the necessary disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with both BSE Limited and National Stock Exchange of India Limited.

The re-appointment underscores the board's confidence in Mr. Mutha's ability to continue leading the company's growth trajectory in the competitive healthcare diagnostics market, while maintaining focus on community health initiatives and corporate social responsibility.

Krsnaa Diagnostics Limited has released the audio recording of its earnings conference call for the third quarter of fiscal year 2026, covering the period ended December 31, 2025. The company has fulfilled its regulatory disclosure obligations by making the recording publicly available and notifying stock exchanges.

Earnings Call Details

The earnings conference call was conducted on February 06, 2026, at 12:30 hours IST through digital means. The call covered the company's financial performance for both the quarter and nine months ended December 31, 2025.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Sujoy Sudipta Bose signed the regulatory filing dated February 06, 2026.

Access Information

The audio recording is accessible through the company's official website under the investor relations section. The recording link has been provided to facilitate stakeholder access to the earnings discussion and management commentary on quarterly performance.

The company has notified both BSE Limited and National Stock Exchange of India Limited about the availability of the earnings call recording, ensuring compliance with listing requirements and providing transparency to investors and stakeholders.